CANCER LETTERS

CANCER LETTERS

CANCER LETT
影响因子:10.1
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:NETHERLANDS
出版社:Elsevier Ireland Ltd
发刊时间:1975
发刊频率:Biweekly
收录数据库:SCIE/Scopus收录
ISSN:0304-3835

期刊介绍

CANCER LETTERS is a journal providing rapid publication of full-length articles in the broad area of cancer research. The journal places emphasis on the molecular and cell biology of cancer, oncogenes, carcinogenesis, radiation biology, molecular pathology, hormones and cancer, viral oncology, biology of cancer and metastasis, molecular cytogenetics, epidemiology; and experimental therapeutics. The primary criterion for publication is interest to a multidisciplinary audience. Papers should be technically sound and substantiated by sufficient experimental detail. Clinical papers will be accepted if they contribute to the understanding of the basic mechanisms underlying disease.
《癌症快报》是一本在癌症研究的广泛领域提供全文文章快速出版的杂志。该杂志的重点是癌症的分子和细胞生物学、癌基因、癌发生、放射生物学、分子病理学、激素和癌症、病毒肿瘤学、癌症和转移生物学、分子细胞遗传学、流行病学;和实验治疗学。发表主要标准是多学科读者感兴趣。论文应该在技术上是合理的,并有足够的实验细节作为依据。如果临床论文有助于理解疾病的基本机制,则可以接受。
年发文量 560
国人发稿量 397.99
国人发文占比 0.71%
自引率 -
平均录取率0
平均审稿周期 平均2.7个月平均3.3周
版面费 US$3840
偏重研究方向 医学-肿瘤学
期刊官网 http://www.elsevier.com/wps/find/journaldescription.cws_home/506050/description#description
投稿链接 https://www.editorialmanager.com/CANLET

期刊高被引文献

Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.10.007
A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.02.033
Treg-mediated acquired resistance to immune checkpoint inhibitors.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.05.003
tRNA-derived fragments and tRNA halves: The new players in cancers.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.03.012
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.11.033
Aptamer-functionalized liposomes for targeted cancer therapy.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.01.045
Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.008
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.01.014
Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.009
Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.02.018
Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.01.039
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.10.004
Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.10.016
Emerging strategies in cancer therapy combining chemotherapy with immunotherapy.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.017
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.10.032
Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.10.014
Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.10.010
Notch Signaling in Breast Cancer: From Pathway Analysis to Therapy.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.07.012
Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.08.003
Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.01.012
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.03.037
TRPM4 channel and cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.012
Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.11.037
miR-193a-3p inhibition of the Slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.01.027
Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.10.013
H22954, a novel long non-coding RNA down-regulated in AML, inhibits cancer growth in a BCL-2-dependent mechanism.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.03.055
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.12.001
Sex Disparities in Cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.08.017
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.12.012
Chromosome fragility in the buccal epithelium in patients with Fanconi anemia.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.12.008
Clinical Lipidomics In Understanding Of Lung Cancer: Opportunity And Challenge.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.08.014
Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.05.004
MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.10.044
Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.01.025
Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.05.005
DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.03.045
BIRC5 is a target for molecular imaging and detection of human pancreatic cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.036
Vps4A mediates the localization and exosome release of β-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.035
Interference with the Bromodomain Epigenome Readers Drives p21 Expression and Tumor Senescence.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.06.019
Endothelin-converting enzyme-1 in cancer aggressiveness.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.03.033
NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.02.024
PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.05.040
Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.04.007
Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.12.015
The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.12.005
HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2018.12.006
Mutant p53R175H promotes cancer initiation in the pancreas by stabilizing HSP70.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.03.047
Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.10.040
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.09.001
A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells.
来源期刊:Cancer lettersDOI:10.1016/j.canlet.2019.08.002

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
90.89%29.33%-5.6%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:Q1区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
ONCOLOGY
Q1

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学1区
ONCOLOGY 肿瘤学
2区
2023年12月升级版
医学1区
ONCOLOGY 肿瘤学
2区
2022年12月旧的升级版
医学1区
ONCOLOGY 肿瘤学
2区